Rchr
J-GLOBAL ID:202201016927770215
Update date: Oct. 09, 2024
Mamiya Hiroaki
Mamiya Hiroaki
Affiliation and department:
Job title:
Associate Professor
Research keywords (5):
Drug pricing
, 薬事
, 医療経済
, 医薬品政策
, 評価科学
Research theme for competitive and other funds (8):
- 2024 - 2028 薬価政策による医薬品アクセスへの影響:多国間パネルデータを用いた国際比較研究
- 2024 - 2026 リアルワールドデータの活用に向けた製造販売後調査の手法の確立に向けた研究
- 2024 - 2026 医療上の必要性が高い革新的医薬品に対する薬価上の評価指標の開発に資する研究
- 2024 - 2025 体外診断用医薬品及び医療機器の一般的名称の策定・選定に係る環境整備に向けた考究
- 2024 - 2025 大規模データを用いた診療報酬インセンティブのバイオシミラー普及への効果分析
- 2023 - 2024 医療用医薬品の安定供給に係る基準策定に向けた調査研究
- 2023 - 2024 臨床試験が実施困難な希少疾患等に対する医薬品の迅速な国内導入を図るための薬事承認審査制度の構築に向けた調査研究
- 2023 - 2024 ニトロソアミン類の体系的リスク評価手法に基づくリスク コミュニケーションガイダンスの策定のための研究
Show all
Papers (10):
-
Hiroaki Mamiya, Ken-ichi Izutsu, Daichi Mitani. Draft Guideline for Industry to Manage Drug Shortages in Japan. Therapeutic Innovation & Regulatory Science. 2024
-
Hiroaki Mamiya, Mamoru Narukawa. Characteristics of Clinical Trials for the US Food and Drug Administration Accelerated Approval and Subsequent Confirmatory Trials: Implications for Drug Approval in Japan. Biological and Pharmaceutical Bulletin. 2024
-
Hiroaki Mamiya, Ataru Igarashi. Impact of reimbursement restriction on drug market sales under the National Health Insurance in Japan. Journal of Medical Economics. 2022. 25. 1. 206-211
-
Hiroaki Mamiya, Ataru Igarashi. Determinants of market prices for drugs under Japan’s national health insurance. Journal of Medical Economics. 2021. 24. 1. 1109-1114
-
H. Mamiya, R.K. Tahara, S.M. Tolaney, N.K. Choudhry, M. Najafzadeh. Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer. Annals of Oncology. 2017. 28. 8. 1825-1831
more...
MISC (15):
-
IZUTSU Kenichi, MAMIYA Hiroaki, YOSHIDA Hiroyuki. Impact of Quality by Design (QbD)-Induced Changes in Manufacturing Control Methods on Prolonged Supply Interruptions of Non-conforming Pharmaceutical Products in Japan. Regulatory Science of Medical Products. 2024. 14. 3. 341-350
-
伊豆津健一, 間宮弘晃. The expected role of complex generic drugs in reducing the patient burden and promoting industries that utilize new technologies. Pharm Tech Japan. 2024. 40. 9
-
MAMIYA Hiroaki. Drug Pricing System in Japan. 日本医学放射線学会総会抄録集. 2024. 83rd
-
間宮弘晃. Special approval system and drugs for treatment of SARS-CoV-2. Pharm Tech Japan. 2024. 40. 7
-
IZUTSU Kenichi, KOIDE Tatsuo, MAMIYA Hiroaki, SATO Yoji, YOSHIDA Hiroyuki. Stability-Related Supply Disruption of Generic Pharmaceuticals in Japan. Regulatory Science of Medical Products. 2024. 14. 1. 91-105
more...
Education (3):
- 2016 - 2022 The University of Tokyo Graduate School of Pharmaceutical Sciences
- 2014 - 2016 Harvard School of Public Health
- 2004 - 2008 Gifu Pharmaceutical University
Professional career (2):
- Ph.D. (Pharmaceutical Science) (Tokyo University)
- Master of Public Health (Harvard University)
Work history (5):
- 2024/04 - 現在 International University of Health and Welfare School of Pharmacy at Narita, Department of Pharmaceutical Sciences Associate Professor
- 2023/04 - 現在 京都大学大学院 医学研究科 客員研究員
- 2023/04 - 2024/03 International University of Health and Welfare School of Pharmacy Department of Pharmaceutical Sciences Associate Professor
- 2021/04 - 2023/03 京都大学iPS細胞研究所 医療応用推進室 (出向)
- 2009/04 - 2023/03 Ministry of Health, Labour, and Welfare
Committee career (3):
- 2023/07 - 2024/05 厚生労働省 後発医薬品の安定供給等の実現に向けた産業構造のあり方に関する検討会 構成員
- 2021/10 - 2023/03 日本薬学会 ファルマシア委員
- 2021/04 - 2023/03 京都大学大学院医学研究科・医学部及び医学部附属病院 医の倫理委員会再生医療小委員会 委員
Return to Previous Page